IDT Australia Limited ( (AU:IDT) ) just unveiled an update.
IDT Australia Limited reported significant progress in the first half of FY25, with new contracts worth $20 million and a substantial increase in revenue to $10.5 million from $5.8 million in the previous corresponding period. The company has expanded its capabilities by commissioning new labs and facilities for advanced therapies and radiopharmaceuticals, positioning itself for future growth and improved financial performance.
More about IDT Australia Limited
IDT Australia Limited operates in the pharmaceutical industry, focusing on advanced therapies and sterile manufacturing. The company provides services such as sterile filling, capsule production, and active pharmaceutical ingredient (API) manufacturing, with a market focus on advanced therapies and radiopharmaceuticals.
Average Trading Volume: 164,823
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$45.49M
Learn more about IDT stock on TipRanks’ Stock Analysis page.